Thank you for joining us in 2022!

Bladder Cancer Immunotherapy

November 11, 2022, 3:25 pm -
3:50 pm
Building on a history of immune response

Session Description

Bladder cancer is the sixth most common cancer in the United States and ninth most common worldwide. While the FDA approved the Bacillus Calmette-Guérin (BCG) cancer vaccine in 1990 for the treatment of superficial, non-invasive bladder cancer, oncologists today are excited about a new class of immunotherapies called immune checkpoint inhibitors. New immunotherapies have significantly reduced the risk of recurrence for bladder cancer while also increasing the percentage of patients who see a complete response post-surgery. Dr. Matthew Galsky, of The Tisch Cancer Institute, discusses the potential to further improve outcomes for patients with this disease and answers questions from the audience. We will discuss how oncologists predict patient response to immunotherapies, common mutations in bladder cancer, length of treatment, and other topics. Don’t forget to submit your questions to Dr. Galsky.


Matthew D. Galsky, MD

The Tisch Cancer Institute

Dr. Matthew Galsky is a medical oncologist with a clinical and research focus on bladder cancer. As a medical oncology fellow at Memorial Sloan-Kettering Cancer Center, he received training in the design and conduct of clinical/translational research, and subsequently joined the faculty at MSKCC. In 2010, he was recruited to the Mount Sinai School of Medicine/Tisch Cancer Institute where he currently serve as Professor of Medicine and Director of Genitourinary Medical Oncology, Co-Director of the Center of Excellence for Bladder Cancer, Associate Director for Translational Research, and Co-Leader of the Cancer Clinical Investigation Program. His research efforts involve team science-based approaches to dissect the mechanisms underlying response and resistance to treatment strategies in bladder cancer and develop strategies to overcome resistance.